Last reviewed · How we verify
Rimegepant 75 MG [Nurtec] (rimegepant-75-mg-nurtec)
At a glance
| Generic name | rimegepant-75-mg-nurtec |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Blurry Vision
- Acid Reflux
- Light Headedness Upon Standing
- Muscle Cramps
- Nausea
- Dyspepsia
- Dizziness
- Exaggerated Reaction to Insect Bites
- Irregular Menses
Key clinical trials
- Rimegepant in Moderate Plaque-type Psoriasis (PHASE2)
- Comparison of Rimegepant and Placebo for Pain in IBS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rimegepant 75 MG [Nurtec] CI brief — competitive landscape report
- Rimegepant 75 MG [Nurtec] updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI